1. All Products
  2. DORARITO - Ritonavir
  3. RITONAVIR (r), 25mg, tab.
Public Pricelist

RITONAVIR (r), 25mg, tab.

https://medicalguidelines.msf.org/en/node/589
https://unicat.msf.org/cat/product/70330
STD DORARITO2T-

Valid Article

Article is intended to be used with children (<12 years) ONLY.
6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AE03
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

RITONAVIR (r)

Therapeutic Action

Antiretroviral, protease inhibitor (PI)

Indications

Booster for protease inhibitors (atazanavir, darunavir, lopinavir, etc.) in HIV infection

Instructions for use

The 25 mg heatstable tablet (intended for paediatric use) replaces the 50 mg tablet and the oral solution.

Ritonavir should not be used alone but in combination with other protease inhibitors.

Fixed-dose combinations (FDC) are available:

  • ATV 300mg / r 100mg, tab.
  • LPV 40mg / r 10mg, granules, sachet
  • LPV 100mg / r 25mg, tab.
  • LPV 200mg / r 50mg, tab.
  • DRV eq. 400mg base / r 50mg, tab.

May be used in addition to the FDC of lopinavir/ ritonavir for additional boosting and to decrease the drug interaction with rifampicin in children on TB treatment.

Storage

Below 25ºC